Details for Patent: 8,609,862

Which drugs does patent 8,609,862 protect, and when does it expire?

Patent 8,609,862 protects ISTURISA and is included in one NDA.

This patent has forty-seven patent family members in thirty-one countries.

Summary for Patent: 8,609,862

Title:	Use of an adrenal hormone-modifying agent
Abstract:	The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): ##STR00001## wherein n is 1 or 3; R is hydrogen or --C(O)N(R.sub.a)(R.sub.b) wherein R.sub.a and R.sub.b are independently --(C.sub.1-C.sub.4)alkyl, or --(C.sub.1-C.sub.4)alkyl-(C.sub.5-C.sub.7)aryl, wherein each of R.sub.a and R.sub.b is optionally substituted by --(C.sub.1-C.sub.4)alkoxy; R.sub.1, R.sub.2, and R.sub.3, are independently hydrogen, halogen, cyano or --(C.sub.6-C.sub.10) aryl, wherein said --(C.sub.6-C.sub.10)aryl is optionally substituted by halogen, with the proviso that no more than one of R.sub.1, R.sub.2, and R.sub.3 is hydrogen; and R.sub.4 and R.sub.5 are hydrogen; or a pharmaceutically acceptable salt thereof.
Inventor(s):	Hu; Qi-Ying (Needham, MA), Ksander; Gary Michael (Amherst, NH), Meredith; Erik (Hudson, MA), Monovich; Lauren G. (Belmont, MA), Papillon; Julien (Somerville, MA), Schumacher; Christoph (Bettingen, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/521,548
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,609,862

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-001	Mar 6, 2020		RX	Yes	No						CUSHING'S DISEASE
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-002	Mar 6, 2020		RX	Yes	No						CUSHING'S DISEASE
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-003	Mar 6, 2020		DISCN	Yes	No						CUSHING'S DISEASE

Foreign Priority and PCT Information for Patent: 8,609,862

PCT Information
PCT Filed	January 13, 2011	PCT Application Number:	PCT/US2011/021100
PCT Publication Date:	July 21, 2011	PCT Publication Number:	WO2011/088188

International Family Members for US Patent 8,609,862

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2523731		301043	Netherlands
European Patent Office	2523731		CA 2020 00025	Denmark
European Patent Office	2523731		132020000000052	Italy
European Patent Office	2523731		122020000026	Germany